After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped 35.66% to $5.25 after-hours on Tuesday.
After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped 35.66% to $5.25 after-hours on Tuesday.
Copyright © Louis Velazquez. All Rights Reserved.